Journal
CURRENT OPINION IN BIOTECHNOLOGY
Volume 66, Issue -, Pages 1-10Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.copbio.2020.05.008
Keywords
-
Funding
- N.I.H. [P41EB028239, R01CA228133, R01EY031097]
- NSF Graduate Research Fellowship program [DGE-1746891]
- American Autoimmune-Related Diseases Association (AARDA)
- Bloomberg similar to Kimmel Institute for Cancer Immunotherapy
Ask authors/readers for more resources
A growing number of gene delivery strategies are being employed for immunoengineering in applications ranging from infectious disease prevention to cancer therapy. Viral vectors tend to have high gene transfer capability but may be hampered by complications related to their intrinsic immunogenicity. Non-viral methods of gene delivery, including polymeric, lipid-based, and inorganic nanoparticles as well as physical delivery techniques, have also been widely investigated. By using either ex vivo engineering of immune cells that are subsequently adoptively transferred or in vivo transfection of cells for in situ genetic programming, researchers have developed different approaches to precisely modulate immune responses. In addition to expressing a gene of interest through intracellular delivery of plasmid DNA and mRNA, researchers are also delivering oligonucleotides to knock down gene expression and immunostimulatory nucleic acids to tune immune activity. Many of these biotechnologies are now in clinical trials and have high potential to impact medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available